Cbfb Myh11 Fusion(Cbfb Myh11 融合)研究综述
Cbfb Myh11 Fusion Cbfb Myh11 融合 - Significance Acute myeloid leukemia (AML) patients whose cancers are classified as either the RUNX1-RUNX1T1 fusion subtype or the CBFB-MYH11 fusion subtype share the common characteristic of significantly decreased levels of mRNA transcripts encoding the DNA repair enzyme OGG1. [1] We retrospectively evaluated the effect of pretransplant MRD, which was measured by a polymerase chain reaction of RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcripts, on transplant outcomes for a cohort of 959 adult patients with t(8;21) or inv(16) AML treated by allogeneic HCT during complete remission (CR), between 2000 and 2018. [2] We found that recurrent CBFB-MYH11 fusions, which result in the expression of fusion protein comprising core-binding factor β (CBFB) and myosin heavy chain 11 (MYH11) and are found in 6∼8% of AML patients, occur mutually exclusively with DNMT3A mutations. [3] Three samples in which CD11b increased in response to ATRA had an inversion of chromosome 16 as well as the CBFB-MYH11 fusion gene, and the fourth sample was from a patient with KMT2A-rearranged, therapy-related AML. [4]意义 癌症被归类为 RUNX1-RUNX1T1 融合亚型或 CBFB-MYH11 融合亚型的急性髓性白血病 (AML) 患者具有共同特征，即编码 DNA 修复酶 OGG1 的 mRNA 转录物水平显着降低。 [1] 我们回顾性评估了移植前 MRD 对 959 名 t(8;21) 或 inv(16) 成年患者的移植结果的影响，其通过 RUNX1-RUNX1T1 或 CBFB-MYH11 融合转录物的聚合酶链反应测量2000 年至 2018 年间在完全缓解 (CR) 期间通过异基因 HCT 治疗的 AML。 [2] 我们发现复发性 CBFB-MYH11 融合，导致包含核心结合因子 β (CBFB) 和肌球蛋白重链 11 (MYH11) 的融合蛋白的表达，并且在 6~8% 的 AML 患者中发现，它们仅与DNMT3A 突变。 [3] CD11b 响应 ATRA 增加的三个样本具有 16 号染色体倒位以及 CBFB-MYH11 融合基因，第四个样本来自 KMT2A 重排的治疗相关 AML 患者。 [4]